Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Aminoguanidine, ALT-711 renoprotective in hyperlipidemia/diabetes model

Sep. 14, 2004

Vivus initiates phase III study of Alista

Sep. 14, 2004

New dosage strengths of Avandamet approved in E.U.

Sep. 14, 2004

Antiobesity treatment with melanin-concentrating hormone receptor-1 antagonist

Sep. 14, 2004

New PYY analogues and their use in body weight disorders

Sep. 14, 2004

Novel 11beta-HSD-1 inhibitors in early development at Novartis

Sep. 14, 2004

Novel GPa inhibitors prepared and tested by Aventis researchers

Sep. 14, 2004

Aventis presents novel PTP inhibitors and their use

Sep. 14, 2004

Activity of fidarestat in diabetic neuropathy evaluated in mice and humans

Sep. 14, 2004

Dosing completed in LAB's first clinical study of GHRH analogue

Sep. 13, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis
BioWorld Science
Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of...